• Optimized GBA1 mRNA for Gaucher Disease Therapy

  2026-08-18

  The reference study develops human GBA1 mRNA designs that improve glucocerebrosidase expression, intracellular stability, and lysosomal delivery in cellular models, while demonstrating detectable enzyme activity in mouse liver and spleen after lipid nanoparticle administration. Its findings support mRNA-LNP therapy as a potential complement or alternative to enzyme replacement, although biodistribution, neurological efficacy, dosing, and long-term safety remain unresolved.

• BRD4–AKT–SIRT3 Signaling in Hyperoxic Lung Injury

  2026-08-18

  The reference study identifies BRD4 as an upstream regulator of an AKT–SIRT3 pathway that influences apoptosis, oxidative stress, and inflammation during hyperoxia-induced lung injury. Its combined cell and animal models provide a mechanistic framework for evaluating BRD4 inhibition, while also highlighting the need to distinguish genetic BRD4 silencing from effects produced by pharmacological BET compounds.

• AMD-070 Hydrochloride: CXCR4 Assay Workflows

  2026-08-17

  AMD-070 hydrochloride enables mechanism-focused studies of CXCR4-dependent migration, signaling, and receptor-blockade phenotypes. This workflow guide combines practical handling advice with a protoplast-based assay principle that helps distinguish membrane effects from genuine pathway activity.

• SAG: From Pathway Switch to Model Design

  2026-08-17

  SAG is a Smoothened receptor agonist for experimentally controlled Hedgehog signaling activation. This assay-centered guide explains how receptor-level pharmacology, orthogonal controls, dosing, and safety boundaries improve interpretation across neural, developmental, and cancer models.

• A1 and AMD3100 in Colorectal Cancer Research

  2026-08-16

  Khorramdelazad and colleagues evaluated A1, a fluorinated CXCR4 inhibitor, against AMD3100 across computational, cellular, and mouse colorectal cancer models. A1 showed stronger predicted CXCR4 binding, inhibited CT-26 proliferation and migration, and produced greater effects on tumor growth and immunosuppressive signaling than AMD3100, while remaining a preclinical candidate requiring further validation.

• PBA-Modified PAD4 Inhibitors Block NET-Driven Tumors

  2026-08-15

  The reference study developed phenylboronic acid-modified PAD4 inhibitors that preferentially interact with tumor cells while suppressing the PAD4–H3cit–NET pathway in neutrophils. Compound 5i reduced tumor growth and lung metastasis in mouse models, illustrating how tumor-directed delivery may improve the therapeutic window of PAD4 inhibition.

• Oligo (dT) 25 Beads for mRNA Workflows

  2026-08-14

  Oligo (dT) 25 Beads provide a rapid, selective route to intact polyadenylated transcripts from eukaryotic RNA, cells, or tissues. This guide translates immune-aging findings into practical mRNA capture, cDNA, RT-PCR, and sequencing workflows while emphasizing assay limits and troubleshooting.

• Carbapenemase Gene Transmission in CREC, Guangdong

  2026-08-14

  This 2025 multicenter study combined gene-location analysis, antimicrobial susceptibility testing, conjugation experiments, mobile-element screening, and strain typing to clarify how carbapenemase-encoding genes circulate in carbapenem-resistant Enterobacter cloacae. Its findings identify plasmid-associated blaNDM-1 and frequent transfer potential as central concerns for surveillance and infection-control research.

• Trelagliptin Restores PI-3K/AKT Signaling in Adipocytes

  2026-08-13

  The reference study investigates how trelagliptin succinate, beyond its established DPP-4 inhibition, improves insulin resistance in differentiated 3T3-L1 adipocytes. Its key contribution is the linking of improved glucose intake and GLUT4 membrane localization with increased IRS-1/AKT signaling and reduced free fatty acid and resistin secretion.

• JDJM Modulates Wnt/β-Catenin Signaling in Knee OA

  2026-08-13

  The reference study connects the anti-inflammatory effects of Jiawei Duhuo Jisheng mixture (JDJM) with suppression of Wnt/β-catenin signaling in osteoarthritic synovium. By combining rabbit synovial fibroblast experiments with a rabbit knee osteoarthritis model, it provides mechanistic evidence that synovial pathway activity may be a tractable complement to cartilage-centered research.

• Flumequine: From Target Inhibition to Cell Response

  2026-08-12

  Flumequine is a DNA topoisomerase II inhibitor suited to mechanistic studies that connect enzyme inhibition with cellular drug response. This evidence-guided article explains how to interpret its reported IC50 without confusing growth arrest, cell killing, or assay-specific effects.

• Beijing 2023 Mycoplasma pneumoniae Resistance Study

  2026-08-12

  A 2024 study of pediatric Mycoplasma pneumoniae isolates from Beijing found complete in vitro resistance to erythromycin and azithromycin, together with a universal A2063G resistance mutation and higher azithromycin MICs in 2023. The work integrates susceptibility testing, molecular typing, and clinical characterization, providing a focused framework for bacterial infection research and antibacterial drug resistance surveillance.

• WRN Inhibition and p53/PUMA Synthetic Lethality in MSI CRC

  2026-08-11

  This PNAS study identifies p53/PUMA-mediated apoptosis as the mechanism linking Werner helicase loss to synthetic lethality in mismatch repair-deficient colorectal cancer. Its genetic, pharmacologic, and xenograft evidence supports WRN targeting in p53-wildtype MSI tumors while also highlighting the need to distinguish WRN-specific effects from broader RecQ helicase inhibition.

• Boc-D-FMK: Practical Pan-Caspase Workflows

  2026-08-11

  Boc-D-FMK provides a cell-permeable, irreversible way to test whether caspase activation drives apoptosis and inflammatory signaling. This guide translates its use into reproducible cell and animal workflows, with assay controls, model-specific applications, and troubleshooting for renal endothelial and hepatocyte studies.

• Luminescent ATP Cell Viability Assay Kit for GBM

  2026-08-10

  The Luminescent ATP Cell Viability Assay Kit I converts intracellular ATP into a rapid, sensitive luminescent readout for glioblastoma proliferation, peptide-delivery, and drug-response studies. Its broad 10–30,000-cell linear range and approximately 10-minute detection window support efficient cytotoxicity assay optimization without a separate lysis step.

15436 records 1/1030 page Next 12345 下5页 Last page